In August 2024, the Beijing Municipal Science and Technology Commission ， Administrative Commission of Zhongguancun Science Park issued the Notice on the Fund Management Measures to Support Enterprise Innovation Capability Enhancement in the Zhongguancun National Independent Innovation Demonstration Zone.
According to Article 9 of the measures, support is provided for the first application of new technologies and products entering the market that address critical gaps in key fields and fill international or domestic technological voids. Eligible projects must feature international or domestic first-of-its-kind innovation, reach leading levels in their respective fields, drive technological advancement, and demonstrate potential for significant economic and social benefits. Additionally, intellectual property rights must be clear, with the enterprise possessing proprietary core technologies for the new products.
AccuMedical's Lattice® Flow Diverter was selected for the 2024 First Market Entry of New Technology and Product Program due to its innovative achievements in the field of neurointervention.
The Lattice® Flow Diverter, featuring a proprietary mechanical balloon delivery system and MIROR surface modification technology, is the first to extend the indications of flow diverters to the treatment of medium and small vertebral artery aneurysms, addressing a critical clinical gap. Among approved products in its class, Lattice® stands out with its broad indications, exceptional efficacy, and safety advantages. It significantly improves patient outcomes while simplifying and innovating surgical procedures. Its outstanding performance has earned widespread acclaim from physicians in clinical practice.
Looking ahead, AccuMedical will continue to increase R&D investment, drive technological innovation and product upgrades in the field of neurointervention, and deliver higher-quality products and services to patients and healthcare professionals worldwide.